Finanzen von Regenxbio Inc (RGNX)RGNXRegenxbio Inc

Evaluating the bottom line, REGENXBIO Inc. maintains a gross margin of 99.04%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 27.09%, while the net margin is 21.02%. These profitability ratios, combined with a Return on Equity (ROE) of -137.63%, provide a clear picture of how effectively RGNX converts its operational activities into shareholder value.

In the context of the broader market, RGNX competes directly with industry leaders such as AQST and SGMT. With a market capitalization of $637.69M, it holds a significant position in the sector. When comparing efficiency, RGNX's gross margin of 99.04% stands against AQST's 70.93% and SGMT's N/A. Such benchmarking helps identify whether REGENXBIO Inc. is trading at a premium or discount relative to its financial performance.

The latest earnings report showed a significant EPS surprise of 258.33%, with reported EPS at $0.43, indicating some operational strength. However, the company has faced net losses in previous quarters, with net income for Q2 2026 at $22,709,000, reflecting volatility in financial performance.